SpringWorks Therapeutics, Inc.
SWTXDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001773427
SpringWorks Therapeutics, Inc. was delisted in 2025; its insiders filed their last Form 4 on Jul 2, 2025; 223 institutions reported holding it in 13F filings for Q2 2025, worth $3.68B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 223
- Q2 2025, −80 vs. previous quarter
- 13F value
- $3.65B
- Reported value at the end of Q2 2025
- Superinvestors holding
- 1
- At the end of Q2 2025
Superinvestors holding SWTX, Q2 2025
1 superinvestor reports holding SpringWorks Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
0.4%
SpringWorks Therapeutics, Inc.'s share of the portfolio
- Shares
- 501,989
- Value
- $23.6M
Latest insider trades
Open-market purchases and sales by SpringWorks Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Edris BadreddinChief Operating Officer | SSale | −20.0K | $54.23 | −$1.08M | −10.5%169.7K after | 4 lots10b5-1 |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Islam SaqibChief Executive Officer | SSale | −49.0K | $54.24 | −$2.66M | −4.9%954.9K after | 5 lots10b5-1 |
| Feb 24, 2025 (view filing) | Feb 20 | 4 days | Islam SaqibChief Executive Officer | SSale | −29.3K | $60.30 | −$1.77M | −2.8%1.03M after | 2 lots10b5-1 |
| Feb 24, 2025 (view filing) | Feb 20 | 4 days | Ashar BhaveshChief Commercial Officer | SSale | −1.02K | $61.19 | −$62.2K | −1.6%62.1K after | 10b5-1 |
| Feb 24, 2025 (view filing) | Feb 20 | 4 days | Lynch DanielDirector | SSale | −47.6K | $60.22 | −$2.87M | −36.5%82.9K after | 2 lots10b5-1 |
| Feb 19, 2025 (view filing) | Feb 14 | 5 days | Islam SaqibChief Executive Officer | SSale | −10.7K | $59.92 | −$639.5K | −1.0%1.06M after | 10b5-1 |
| Feb 19, 2025 (view filing) | Feb 14 | 5 days | Lynch DanielDirector | SSale | −400 | $60.00 | −$24.0K | −0.3%130.5K after | 10b5-1 |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | Pichl DanielChief People Officer | SSale | −29.8K | $54.36 | −$1.62M | −37.0%50.8K after | 3 lots10b5-1 |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | Lynch DanielDirector | SSale | −175.0K | $54.46 | −$9.53M | −57.2%130.9K after | 3 lots10b5-1 |
| Feb 12, 2025 (view filing) | Feb 10 | 2 days | Islam SaqibChief Executive Officer | SSale | −48.0K | $53.30 | −$2.56M | −4.6%1.00M after | 10b5-1 |
Top 10 13F holders, Q2 2025
The largest institutional positions in SpringWorks Therapeutics, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,260,644 | $341.2M | 0.01% | +1,014,573+16.2% | Added |
| Vanguard Group Inc | 7,131,004 | $335.1M | 0.01% | +48,423+0.7% | Added |
| Glazer Capital, LLC | 4,107,199 | $193.0M | 6.91% | +4,107,199 | New |
| FIL Ltd | 3,013,959 | $141.6M | 0.12% | +3,013,959 | New |
| State Street Corp | 2,994,000 | $140.7M | 0.01% | +77,659+2.7% | Added |
| TIG Advisors, LLC | 2,611,074 | $122.7M | 6.70% | +2,359,400+937.5% | Added |
| HBK Investments L P | 2,608,340 | $122.6M | 2.18% | +2,608,340 | New |
| Goldman Sachs Group Inc | 2,275,449 | $106.9M | 0.02% | +1,649,354+263.4% | Added |
| Beryl Capital Management LLC | 2,117,575 | $99.5M | 14.99% | +2,117,575 | New |
| Magnetar Financial LLC | 2,052,642 | $96.5M | 0.47% | +2,052,642 | New |